RxDoctor Payments Data

Gretchen Gignac, MD

Medical Oncology · Boston, MANPI 1821288960

Payments from drug & device makers

$101,666in general payments, 2019–2025

Across 19 payments — averaging $5350.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$82K
  • Seagen Inc.$18K
  • Merck$1K
  • Amgen$983

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.3$81,543
Seagen Inc.1$17,875
Merck14$1,265
Amgen1$983

How this compares

$101,666 in reported general payments places this provider in the 55th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$42,461
Medicare patients
134
Services billed
390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide94$988,712
OrgovyxRelugolix294$765,262
ErleadaApalutamide23$341,878
XtandiEnzalutamide32$329,287
Abiraterone Acetate57$20,778
Bicalutamide53$672
Tamsulosin Hcl20$193
Prednisone60$193
Dexamethasone16$144
Ondansetron Hcl12$63

Paid to pharmacies, not to this prescriber.

Other medical oncology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →